Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  American Journal of Respiratory and Critical Care Medicine

• Publication date

  2002-03-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1164/AJRCCM.165.6.2106079PMID 11897647
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.

  2000cited by this paper
• Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing.

  2000cited by this paper
• Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial

  2000cited by this paper
• Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue.

  2000cited by this paper
• Epoprostenol (Prostacyclin) and Pulmonary Hypertension

  2000cited by this paper
• Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease

  2000cited by this paper
• Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects.

  1999cited by this paper
• Treatments for severe pulmonary hypertension.

  1999cited by this paper
• Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension.

  1999cited by this paper
• Compassionate Use of Continuous Prostacyclin in the Management of Secondary Pulmonary Hypertension: A Case Series

  1999cited by this paper
• Treatment of pulmonary hypertension secondary to connective tissue diseases

  1999cited by this paper
• Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

  1998cited by this paper
• Orally active prostacyclin analogue in primary pulmonary hypertension.

  1997influential reference
• Primary pulmonary hypertension.

  1997cited by this paper
• A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.

  1996influential reference
• The pharmacokinetics and pharmacodynamics of the prostacyclin analog 15AU81 in the anesthetized beagle dog.

  1993cited by this paper
• Infectious complications among patients receiving home intravenous therapy with peripheral, central, or peripherally placed central venous catheters.

  1991cited by this paper
• The effects of 15AU81, a chemically stable prostacyclin analog, on the cardiovascular and renin-angiotensis systems of anesthetized dogs

  1991cited by this paper
• The effects of I5AU8I, a chemically stable prostacyclin analog, on the cardiovascular and renin-angiotensin systems of anesthetized dogs [corrected].

  1991cited by this paper
• Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

  1991cited by this paper
• Changes in dyspnea-fatigue ratings as indicators of quality of life in the treatment of congestive heart failure.

  1989influential reference
• PRIMARY PULMONARY HYPERTENSION: A NATIONAL PROSPECTIVE STUDY

  1987cited by this paper
• Patients' self-assessment of their congestive heart failure : Content, reliability, and validity of a new measure, the Minnesota Living with Heart Failure Questionnaire

  1987cited by this paper
• The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure.

  1985cited by this paper
• Psychophysical bases of perceived exertion.

  1982cited by this paper

• Advances in and Clinical Experience with Subcutaneous Infusion Pump Therapy for Pulmonary Arterial Hypertension.

  2026cites this paper
• DIAGNÓSTICO

  2025cites this paper
• The Importance of Dose Escalation in the Treatment of Pulmonary Arterial Hypertension with Treprostinil

  2025cites this paper
• Implantation of integrated magnetically levitated biventricular assist devices (DuoCor) – a single-center clinical experience

  2025cites this paper
• Right heart remodeling in end-stage pulmonary arterial hypertension and the impact of treatment intensity

  2025cites this paper
• Inhaled Treprostinil: Improvements in Hemodynamics and Quality of Life for Patients with Pulmonary Arterial Hypertension on Dual or Triple Therapy

  2025cites this paper
• Treatment of pulmonary hypertension after seven world symposia

  2025cites this paper
• Global Research Trends on Vascular Resistance: A Bibliometric Analysis

  2025cites this paper
• Sharing Diagnostic and Therapeutic Pathways in Pulmonary Arterial Hypertension: A Roadmap for the Triveneto Region

  2025cites this paper
• Pulmonary Hypertension Associated with Interstitial Lung Disease: A Review on Diagnosis and Treatment with a Focus on Emerging Therapies

  2025cites this paper
• Clinical Pharmacokinetics of Inhaled Drugs for Pulmonary Hypertension

  2025cites this paper
• Novel Therapies for Right Ventricular Failure

  2025cites this paper
• Neuropsychiatric reaction to treprostinil in pulmonary hypertension leading to treatment discontinuation

  2025cites this paper
• The Efficacy of Pharmacological Interventions in Pulmonary Arterial Hypertension (WHO Group 1): A Systematic Review of Randomized Controlled Trials

  2025cites this paper
• Enhanced Electrochemical Sensing of Treprostinil: A Novel Approach for Sensitive and Selective Detection

  2025cites this paper
• Resolution of inflammation in pulmonary arterial hypertension, the influence of sex—An IUPHAR immunopharmacology committee review

  2025cites this paper
• Efficacy of 10% lidocaine gel for injection site pain associated with treprostinil in the treatment of pulmonary hypertension: a report of four cases

  2025cites this paper
• Contemporary Treatment Strategies in Pulmonary Hypertension: A Clinician's Guide.

  2025cites this paper
• Renal dysfunction and outcomes in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: an individual participant data meta-analysis

  2025cites this paper
• From Pathways to Patients: Contemporary Approaches to Pulmonary Hypertension.

  2025cites this paper
• Management of Pulmonary Arterial Hypertension: Current Strategies and Future Prospects

  2025cites this paper
• How a Most Unlikely Drug Changed the Outcome of Pulmonary Arterial Hypertension

  2025cites this paper
• Pulmonary hypertension – Diagnosis and management

  2025cites this paper
• A long-term follow-up study of sotatercept for treatment of pulmonary arterial hypertension: interim results of SOTERIA

  2025cites this paper
• Important negative trials in pulmonary hypertension.

  2025cites this paper
• Pulmonary arterial hypertension treatment. A new era

  2025cites this paper
• Antiproliferative therapies in pulmonary arterial hypertension

  2025cites this paper
• Tratamiento de la hipertensión pulmonar

  2025cites this paper
• Management of Critically Ill Patients With Pulmonary Arterial Hypertension in Transport: A Narrative Review.

  2025cites this paper
• Consensus recommendations for diagnosis and management of pulmonary arterial hypertension patients in Egypt

  2025cites this paper
• The landscape of referrals for lung transplantation in pulmonary arterial hypertension: a report from the Pulmonary Hypertension Association Registry.

  2025cites this paper
• Inhaled treprostinil in group 3 pulmonary hypertension associated with lung disease: results of the INCREASE and PERFECT studies

  2025cites this paper
• Risk of respiratory, thoracic, and mediastinal disorders associated with endothelin receptor antagonists and prostacyclin-related drugs in pulmonary hypertension: a disproportionality analysis based on FAERS

  2024cites this paper
• The Minimally Important Difference in the Six-minute Walk Test Predicts Clinical Worsening in Pulmonary Arterial Hypertension.

  2024cites this paper
• A new day has come: Sotatercept for the treatment of pulmonary arterial hypertension.

  2024cites this paper
• Prostacyclin pathway vasodilators in patients with chronic thromboembolic pulmonary hypertension (CTEPH): A systemic review and meta‐analysis of randomized controlled trials

  2024cites this paper
• Abordaje de la hipertensión arterial pulmonar para el clínico: fisiopatología, diagnóstico y tratamiento

  2024cites this paper
• TREATMENT OF PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONGENITAL HEART DEFECTS

  2024cites this paper
• An in-depth evaluation of the efficacy and safety of various treatment modalities for chronic thromboembolic pulmonary hypertension: A systematic review and network meta-analysis

  2024cites this paper
• Emerging insights into pulmonary hypertension: the potential role of mitochondrial dysfunction and redox homeostasis

  2024cites this paper
• Treatment with Oral or Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension and Cardiovascular Comorbidities.

  2024cites this paper
• Mitigation of CXCL10 secretion by metabolic disorder drugs in microglial-mediated neuroinflammation.

  2024cites this paper
• Mechanisms and treatment of pulmonary arterial hypertension

  2024cites this paper
• Recent developments in connective tissue disease associated pulmonary arterial hypertension

  2024cites this paper
• Pulmonary Hypertension in Connective Tissue Diseases Other than Systemic Sclerosis

  2024cites this paper
• Vitamin C deficiency can lead to pulmonary hypertension: a systematic review of case reports

  2024cites this paper
• Younger age at initiation of subcutaneous treprostinil is associated with better response in pediatric Group 1 pulmonary arterial hypertension

  2024cites this paper
• Health-Related Quality of Life Across the Spectrum of Pulmonary Hypertension.

  2024cites this paper
• New Therapies in Outpatient Pulmonary Medicine.

  2024cites this paper
• Hypertension artérielle pulmonaire idiopathique et états apparentés

  2024cites this paper
• The Role of Palliative Care in Cardiovascular Disease.

  2024cites this paper
• Therapeutic approaches for pulmonary hypertension in patients with chronic kidney disease

  2024cites this paper
• Treatment algorithm for pulmonary arterial hypertension

  2024cites this paper
• Pulmonary Hypertension in Underrepresented Minorities: A Narrative Review

  2024cites this paper
• Contemporary Treatment of Pulmonary Arterial Hypertension: A US Perspective.

  2024cites this paper
• Impact of Parenteral Prostanoids in Pulmonary Arterial Hypertension: The Relevance of Timing

  2023cites this paper
• Impact of selexipag use within 12 months of pulmonary arterial hypertension diagnosis on hospitalizations and medical costs: A retrospective cohort study

  2023cites this paper
• Role of prostanoids, nitric oxide and endothelin pathways in pulmonary hypertension due to COPD

  2023cites this paper
• Long-acting inhaled medicines: Present and future.

  2023cites this paper
• Treatment of pulmonary arterial hypertension: recent progress and a look to the future.

  2023cites this paper
• Contribution of pressure and flow changes to resistance reduction after pulmonary arterial hypertension treatment: a meta-analysis of 3898 patients

  2023cites this paper
• Pharmacological management of connective tissue disease-associated pulmonary arterial hypertension

  2023cites this paper
• Clinical features of pulmonary arterial hypertension associated with systemic sclerosis

  2023cites this paper
• Inhaled therapies targeting prostacyclin pathway in pulmonary hypertension due to COPD: systematic review

  2023cites this paper
• Recent Advances in the Treatment of Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases

  2023cites this paper
• Long-Term Safety, Outcome, and Clinical Effects of Subcutaneous and Intravenous Treprostinil Treatment in Patients with Severe Chronic Pulmonary Arterial Hypertension

  2023cites this paper
• Pulmonary arterial hypertension.

  2023cites this paper
• The risk profile change in patients with severe chronic thromboembolic pulmonary hypertension treated with subcutaneous treprostinil

  2023cites this paper
• Parenteral treprostinil induction for rapid attainment of therapeutic doses of oral treprostinil.

  2023cites this paper
• Pharmacotherapy of refractory pulmonary arterial hypertension

  2023influential citation
• Time to clinical improvement: an appropriate surrogate endpoint for pulmonary arterial hypertension medication trials

  2023cites this paper
• Cannabidiol (CBD) for the treatment of subcutaneous treprostinil (Remodulin®) site pain: a case report

  2023cites this paper
• Pulmonary arterial hypertension trials put to the test: Using the fragility index to assess trials robustness.

  2023cites this paper
• Medical Management of Pulmonary Arterial Hypertension: Current Approaches and Investigational Drugs

  2023cites this paper
• Management of Acute Right Ventricular Failure

  2023cites this paper
• Pulmonary artery hypertension-associated with human immunodeficiency virus infection with attenuated effect of subcutaneous treprostinil injection during long-term observation: A case report.

  2023cites this paper
• Management of Pulmonary Arterial Hypertension

  2023cites this paper
• [Physiopathology and treatment of pulmonary arterial hypertension].

  2023cites this paper
• Advances in the discovery of drugs that treat pulmonary arterial hypertension

  2023cites this paper
• Patient Satisfaction with a Dedicated Infusion Pump for Subcutaneous Treprostinil to Treat Pulmonary Arterial Hypertension

  2023cites this paper
• The Evolving Management and Treatment Options for Patients with Pulmonary Hypertension: Current Evidence and Challenges

  2023cites this paper
• Pharmacotherapy for Pulmonary Hypertension in Infants with Bronchopulmonary Dysplasia: Past, Present, and Future

  2023cites this paper
• Idiopathic Pulmonary Fibrosis: 8 Years On After Nintedanib and Pirfenidone Approval—What Is on the Horizon?

  2023cites this paper
• Inhaled iloprost as an add-on therapy for advanced pulmonary arterial hypertension: An Indian perspective.

  2023cites this paper
• Metabolomic Signatures Associated With Pulmonary Arterial Hypertension Outcomes

  2023cites this paper
• Egln1Tie2Cre Mice Exhibit Similar Therapeutic Responses to Sildenafil, Ambrisentan, and Treprostinil as Pulmonary Arterial Hypertension (PAH) Patients, Supporting Egln1Tie2Cre Mice as a Useful PAH Model

  2023cites this paper
• Pulmonary arterial hypertension associated with connective tissue diseases (CTD-PAH): Recent and advanced data.

  2023cites this paper
• Gezielte medikamentöse Therapie der pulmonalarteriellen Hypertonie bei Patient*innen ohne Komorbiditäten

  2023cites this paper
• Prenatal treprostinil improves pulmonary arteriolar hypermuscularization in the rabbit model of congenital diaphragmatic hernia.

  2023cites this paper
• Heterogeneity of treatment effects by risk in pulmonary arterial hypertension

  2023cites this paper
• Pulmonary hypertension

  2023cites this paper
• Intravenous Treprostinil in Severe Inoperable Chronic Thromboembolic Pulmonary Hypertension Using Implantable Pumps—Single-Center Experience over More Than a Decade

  2023cites this paper
• Targeted Therapies for Neonatal Pulmonary Hypertension: Beyond Nitric Oxide.

  2023cites this paper
• Perioperative Decision-Making in Pulmonary Hypertension.

  2023cites this paper
• Human Immunodeficiency Virus–Associated Pulmonary Arterial Hypertension

  2022cites this paper
• New progress in diagnosis and treatment of pulmonary arterial hypertension

  2022cites this paper
• Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients

  2022cites this paper
• The 6-min walk test as a primary end-point in interstitial lung disease

  2022cites this paper
• 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.

  2022cites this paper
• Hipertensión arterial pulmonar

  2022cites this paper